Markus Dangl

513 total citations
14 papers, 339 citations indexed

About

Markus Dangl is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Markus Dangl has authored 14 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Oncology and 2 papers in Genetics. Recurrent topics in Markus Dangl's work include Cancer-related Molecular Pathways (5 papers), Chronic Lymphocytic Leukemia Research (2 papers) and CAR-T cell therapy research (2 papers). Markus Dangl is often cited by papers focused on Cancer-related Molecular Pathways (5 papers), Chronic Lymphocytic Leukemia Research (2 papers) and CAR-T cell therapy research (2 papers). Markus Dangl collaborates with scholars based in Germany, Switzerland and Austria. Markus Dangl's co-authors include Gerald Brosch, Peter Loidl, Hubertus Haas, Thomas Friess, Christian H.K. Lehmann, Alexandra Lusser, Fabian Birzele, Anna Kiialainen, Patrick Trojer and Stefan Graessle and has published in prestigious journals such as Blood, Journal of Molecular Biology and Biochemistry.

In The Last Decade

Markus Dangl

14 papers receiving 334 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Markus Dangl Germany	10	256	91	90	47	34	14	339
Katherine L. Marsh United Kingdom	8	513 2.0×	199 2.2×	31 0.3×	19 0.4×	41 1.2×	10	576
Susumu Iiizumi Japan	9	468 1.8×	183 2.0×	40 0.4×	11 0.2×	16 0.5×	13	529
Jan Taplick Austria	8	554 2.2×	191 2.1×	55 0.6×	34 0.7×	8 0.2×	8	621
Jenna L. Carter United States	7	268 1.0×	34 0.4×	101 1.1×	124 2.6×	5 0.1×	18	396
Catherine Berset Switzerland	8	339 1.3×	74 0.8×	27 0.3×	37 0.8×	6 0.2×	12	416
Fadi Abdi United States	6	228 0.9×	17 0.2×	24 0.3×	93 2.0×	16 0.5×	7	329
Maureen D. Megonigal United States	12	532 2.1×	132 1.5×	31 0.3×	317 6.7×	20 0.6×	16	715
Caroline Huard Canada	12	369 1.4×	71 0.8×	23 0.3×	20 0.4×	4 0.1×	15	438
Sake van Wageningen Netherlands	10	388 1.5×	66 0.7×	16 0.2×	27 0.6×	10 0.3×	11	455

Countries citing papers authored by Markus Dangl

Since Specialization

Citations

This map shows the geographic impact of Markus Dangl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Dangl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Dangl more than expected).

Fields of papers citing papers by Markus Dangl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Dangl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Dangl. The network helps show where Markus Dangl may publish in the future.

Co-authorship network of co-authors of Markus Dangl

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Dangl. A scholar is included among the top collaborators of Markus Dangl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Dangl. Markus Dangl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Robertson, Jane, Max Salm, & Markus Dangl. (2019). Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer. Immuno-Oncology Technology. 3. 1–7. 22 indexed citations

Lehmann, Christian H.K., Thomas Friess, Fabian Birzele, Anna Kiialainen, & Markus Dangl. (2016). Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. Journal of Hematology & Oncology. 9(1). 50–50. 70 indexed citations

Herting, Frank, Sylvia Herter, Thomas Friess, et al.. (2016). Antitumour activity of the glycoengineered type II anti‐CD20 antibody obinutuzumab (GA101) in combination with the MDM2‐selective antagonist idasanutlin (RG7388). European Journal Of Haematology. 97(5). 461–470. 21 indexed citations

Wong, Bernice H., Dachuan Huang, Jing Tan, et al.. (2015). Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma. Cancer Investigation. 33(8). 378–386. 11 indexed citations

Pan, Rongqing, Kensuke Kojima, Vivian Ruvolo, et al.. (2014). Activation of p53 By Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199). Blood. 124(21). 2162–2162. 6 indexed citations

Herting, Frank, Sylvia Herter, Thomas Friess, et al.. (2014). Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity. Blood. 124(21). 1780–1780. 1 indexed citations

Dangl, Markus, Yuchen Chien, Christian H.K. Lehmann, & Thomas Friess. (2014). Abstract 5505: Synergistic anticancer activity of clinical stage, non-genotoxic apoptosis inducing agents RG7388 (MDM2 antagonist) and ABT-199 (GDC-0199, BCL2 inhibitor) in p53 wild-type AML tumor models. Cancer Research. 74(19_Supplement). 5505–5505. 6 indexed citations

Higgins, Brian, Christian Tovar, Kelli Glenn, et al.. (2013). Abstract B55: Antitumor activity of the MDM2 antagonist RG7388.. Molecular Cancer Therapeutics. 12(11_Supplement). B55–B55. 3 indexed citations

Siegrist, Romain, Paul Seiler, François Diederich, et al.. (2007). A Novel Synthesis of Highly Substituted Perhydropyrrolizines, Perhydroindolizines, and Pyrrolidines: Inhibition of the Peptidyl‐Prolyl cis/trans Isomerase (PPIase) Pin1. Helvetica Chimica Acta. 90(2). 217–259. 15 indexed citations

10.

Wisniewska, M., Birgit Bossenmaier, Guy Georges, et al.. (2005). The 1.1Å Resolution Crystal Structure of the p130cas SH3 Domain and Ramifications for Ligand Selectivity. Journal of Molecular Biology. 347(5). 1005–1014. 19 indexed citations

11.

Trojer, Patrick, Markus Dangl, Ingo Bauer, et al.. (2004). Histone Methyltransferases in Aspergillus nidulans: Evidence for a Novel Enzyme with a Unique Substrate Specificity. Biochemistry. 43(33). 10834–10843. 37 indexed citations

12.

Dangl, Markus, Gerald Brosch, Hubertus Haas, Peter Loidl, & Alexandra Lusser. (2001). Comparative analysis of HD2 type histone deacetylases in higher plants. Planta. 213(2). 280–285. 72 indexed citations

13.

Brosch, Gerald, Markus Dangl, Stefan Graessle, et al.. (2001). An Inhibitor-Resistant Histone Deacetylase in the Plant Pathogenic Fungus Cochliobolus carbonum. Biochemistry. 40(43). 12855–12863. 15 indexed citations

14.

Graessle, Stefan, Markus Dangl, Hubertus Haas, et al.. (2000). Characterization of two putative histone deacetylase genes from Aspergillus nidulans. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1492(1). 120–126. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact